| Early engagement with a prescriber vs. Did not engage | Early engagement without a prescriber vs. Did not engage | Early engagement with a prescriber vs. Early engagement without a prescriber | ||||||
---|---|---|---|---|---|---|---|---|---|
Q1 | Q2 | Q3 | Q1 | Q2 | Q3 | Q1 | Q2 | Q3 | |
Reach | |||||||||
 Number of patients with OUD | |||||||||
  EE (95% CI) | 17.32 (−2726.97, 2761.61) | 6.72 (−1381.52, 1394.96) | −3.88 (−2748.17, 2740.41) | 13.02 (−3292.76, 3318.81) | 16.54 (−1687.17, 1720.25) | 20.05 (−3286.25, 3326.35) | 4.30 (−1234.21, 1242.81) | −9.82 (−640.28, 620.64) | −23.93 (−1263.53, 1215.66) |
  ES (95% CI) | 0.21 (−33.05, 33.47) | 0.08 (−16.75, 16.91) | −0.05 (−33.31, 33.22) | 0.16 (−39.91, 40.23) | 0.20 (−20.45, 20.85) | 0.24 (−39.83, 40.32) | 0.05 (−14.96, 15.06) | −0.12 (−7.76, 7.52) | −0.29 (−15.32, 14.74) |
 Number of patients prescribed MOUD | |||||||||
  EE (95% CI) | 15.68 (−61.70, 93.06) | 2.51 (−52.70, 57.72) | −10.66 (−88.04, 66.72) | 14.99 (−80.07, 110.05) | 5.38 (−63.47, 74.23) | −4.24 (−99.29, 90.82) | 0.69 (−35.35, 36.74) | −2.87 (−28.97, 23.23) | −6.43 (−42.47, 29.62) |
  ES (95% CI) | 0.98 (−3.84, 5.79) | 0.16 (−3.28, 3.59) | −0.66 (−5.48, 4.15) | 0.93 (−4.98, 6.85) | 0.34 (−3.95, 4.62) | −0.26 (−6.18, 5.65) | 0.04 (−2.20, 2.9) | −0.18 (−1.80, 1.45) | −0.40 (−2.64, 1.84) |
 Percent of patients prescribed MOUDa | |||||||||
  EE (95% CI) | 4.90 (−3.00, 12.79) | −2.34 (−8.90, 4.22) | −9.58 (−17.11, −2.05) | 6.91 (−0.59, 14.41) | −5.67 (−11.48, 0.14) | −18.25 (−25.22, −11.29) | −2.01 (−6.06, 2.03) | 3.33 (0.85, 5.81) | 8.68 (4.07, 13.28) |
  ES (95% CI) | 0.13 (−0.08, 0.35) | −0.06 (−0.24, 0.11) | −0.26 (−0.46, −0.06) | 0.19 (−0.02, 0.39) | −0.15 (−0.31, 0.00) | −0.49 (−0.68, −0.31) | −0.05 (−0.16, 0.06) | 0.09 (0.02, 0.16) | 0.23 (0.11, 0.40) |
Adoption | |||||||||
 Number of prescribers | |||||||||
  EE (95% CI) | 2.42 (−6.71, 11.54) | 2.42 (−5.84, 10.69) | 2.43 (−6.69, 11.56) | 2.61 (−8.39, 13.61) | 2.60 (−7.38, 12.58) | 2.59 (−8.41, 13.59) | −0.19 (−3.72, 3.34) | −0.17 (−3.32, 2.97) | −0.15 (−3.68, 3.38) |
  ES (95% CI) | 0.52 (−1.45, 2.50) | 0.53 (−1.264, 2.314) | 0.53 (−1.45, 2.50) | 0.57 (−1.82, 2.95) | 0.56 (−1.60, 2.72) | 0.56 (−1.821, 2.940) | −0.04 (−0.81, 0.72) | −0.04 (−0.72, 0.64) | −0.03 (−0.80, 0.93) |
 Number of x-waivered prescribers | |||||||||
  EE (95% CI) | 0.53 (−2.68, 3.73) | 0.14 (−2.70, 2.98) | −0.24 (−3.45, 2.96) | 0.92 (−3.05, 4.90) | 0.20 (−3.35, 3.74) | −0.53 (−4.50, 3.44) | −0.40 (−1.90, 1.11) | −0.06 (−1.40, 1.11) | 0.28 (−1.22, 1.79) |
  ES (95% CI) | 0.17 (−0.89, 1.24) | 0.05 (−0.89, 0.99) | −0.08 (−1.14, 0.98) | 0.31 (−1.01, 1.62) | 0.07 (−1.11, 1.24) | −0.18 (−1.49, 1.14) | −0.13 (−0.63, 0.37) | −0.02 (−0.46, 0.43) | 0.10 (−0.40, 0.59) |
 Number of active x-waivered prescribers | |||||||||
  EE (95% CI) | 0.62 (−0.48, 1.73) | 0.14 (−0.77, 1.05) | −0.34 (−1.44, 0.76) | 0.94 (−0.43, 2.32) | 0.47 (−0.68, 1.61) | −0.01 (−1.38, 1.36) | −0.32 (−0.84, 0.19) | −0.33 (−0.76, 0.10) | −0.33 (−0.85, 0.19) |
  ES (95% CI) | 0.34 (−0.26, 0.94) | 0.08 (−0.42, 0.57) | −0.19 (−0.79, 0.42) | 0.51 (−0.23, 1.26) | 0.25 (−0.37, 0.88) | −0.01 (−0.75, 0.74) | −0.18 (−0.46, 0.11) | −0.18 (−0.41, 0.06) | −0.18 (−0.46, 0.10) |
 Percent of x-waivered prescribers | |||||||||
  EE (95% CI) | 1.79 (−0.20, 3.78) | 0.52 (−1.31, 2.35) | −0.75 (−2.75, 1.24) | 6.08 (3.61, 8.56) | 3.08 (0.80, 5.37) | 0.08 (−2.39, 2.56) | −4.30 (−5.17, −3.42) | −2.57 (−3.36, −1.77) | −0.84 (−1.71, 0.04) |
  ES (95% CI) | 0.08 (−0.01, 0.17) | 0.02 (−0.06, 0.11) | −0.03 (−0.13, 0.06) | 0.28 (0.16, 0.39) | 0.14 (0.04, 0.24) | 0.00 (−0.11, 0.12) | −0.20 (−0.24, −0.16) | −0.12 (−0.15, −0.08) | −0.04 (−0.08, 0.00) |
Implementation | |||||||||
 IMAT implementation quality | |||||||||
  EE (95% CI) | – | – | −0.36 (−0.53, −0.20) | – | – | −0.11 (−0.31, 0.10) | – | – | −0.25 (−0.33, −0.18) |
  ES (95% CI) | – | – | −0.60 (−0.87, −0.33) | – | – | −0.18 (−0.52, 0.16) | – | – | −0.42 (−0.55, −0.29) |